Clinical trials: Episodic Migraine Headache
Episodic Migraine
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
- Trial name
- NCT02176018
- Testing
- Dextromethorphan and quinidine
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Cady, Roger, M.D.
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Episodic Migraine
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
- Trial name
- EMPOwER (NCT03333109)
- Testing
- Erenumab
- Where
- 81 sites in Argentina, India and 9 more
- Volunteers
- 900 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Metformin for the Prevention of Episodic Migraine (MPEM)
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
- Trial name
- MPEM (NCT02593097)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).
- Trial name
- NCT04458857
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Headache
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
- Trial name
- NCT02163993
- Testing
- Galcanezumab
- Where
- 40 sites in United States
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Migraine
A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache
This is a single-center, open-label, pilot trial to collect and evaluate data on the safety and efficacy of duloxetine in the preventive treatment of subjects experiencing episodic migraine headaches.
- Trial name
- NCT00443352
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thomas Jefferson University
Migraine Headache
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Migraine is one of the three most disabling diseases worldwide. Constituted by recurrent episodes of headache, characterized by unilateral location, throbbing character, moderate or severe intensity, worsening with physical…
- Trial name
- NCT04698525
- Testing
- Valproate Sodium, Memantine
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Episodic Migraine
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
- Trial name
- NCT03700320
- Testing
- Standard of Care (SOC) Migraine Preventive Medication, Atogepant
- Where
- 112 sites in United States
- Volunteers
- 744 people
- Sponsor
- Allergan
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
- Trial name
- PERSIST (NCT03963232)
- Testing
- Galcanezumab
- Where
- 40 sites in China, India and 1 more
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine, Headache, Episodic Migraine
Occipital Blocks for Acute Migraine
Migraine affects 10-28% of children and adolescents and yet 20-30% of patients are ineffectively treated with current oral and nasal options.
- Trial name
- NCT03526874
- Testing
- Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Children's Hospital of Philadelphia
Migraine
Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs
Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has been noted in several studies that in patients with migraine, seventy nine percent of the patients experienced allodynia on the facial…
- Trial name
- NCT00386880
- Testing
- Sounds
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Thomas Jefferson University
Episodic Migraine
Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack
This is a pilot trial to collect data on the use of intravenous ibuprofen (IVIb) in the treatment of an acute migraine attack. Data will be collected on the efficacy of IVIb in subjects who are treated with study medication…
- Trial name
- intravenous (NCT01230411)
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Thomas Jefferson University
Migraine
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
This study is a prospective, multi-centre, randomised, double-blind, sham-controlled investigation designed for comparison of two parallel treatment groups: gammaCore (active nVNS treatment) and a Sham device (control treatment)…
- Trial name
- NCT02686034
- Testing
- gammaCore-S
- Where
- 10 sites in Italy
- Volunteers
- 285 people
- Sponsor
- ElectroCore INC
Migraine Headache
Music Intervention on Migraine Headaches
Migraine is a frequent pathology, highly linked to anxio-depressive factors. Non-drug approaches are part of the therapeutic arsenal.
- Trial name
- CHU (NCT03763058)
- Testing
- Music Therapy
- Where
- Reunion
- Volunteers
- 20 people
- Sponsor
- Association de Musicothérapie Applications et Recherches Cliniques
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories